StockData
SCYNEXIS Inc logo

SCYNEXIS Inc (SCYX) company profile

SCYXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 13/3072% below fair value
$2.85−0.06 (-2.06%)

Close on Nov 17, 2026Market cap $28.36MP/E –Yield –

About Scynexis

Pharmaceutical Preparations, SIC 2834

SCYNEXIS, Inc. is a biotechnology company that develops treatments for severe diseases, focusing on drug-resistant and difficult-to-treat fungal infections. The company creates therapies using its proprietary platform of triterpenoid antifungal agents known as fungerps. Its lead commercialized product is ibrexafungerp, marketed as BREXAFEMME for vaginal yeast infections and licensed to GSK. SCYNEXIS also advances clinical candidates such as SCY-247, an antifungal evaluated in oral and intravenous formulations for invasive candidiasis. Its therapies target hospitalized and immunocompromised patients treated by infectious disease specialists, oncologists, and critical care physicians at major medical centers.

The company maintains an international operational reach through licensing agreements covering regions including the United States, Greater China, and Russia. SCYNEXIS does not own or operate manufacturing, storage, or laboratory facilities, relying instead on external contract manufacturers to produce its clinical supplies and drug products. The provided text does not disclose the location of the company's corporate headquarters.

Summary of the business section of Scynexis's latest annual report, written by StockData.

Company profile

Company

Legal name
SCYNEXIS Inc
Founded
1999
Headquarters
Jersey City, NJ
Address
1 Evertrust Plaza, 13th Floor 07302-6548
Phone
(201) 884-5485
Employees
18, Dec 31, 2025
Industry
Pharmaceutical Preparations
Fiscal year ends
December 31
Auditor
Deloitte & Touche LLP, Morristown, New Jersey

Stock & identifiers

Ticker
SCYX
Exchange
Nasdaq
IPO date
May 2, 2014
Shares outstanding
10M, Aug 1, 2026
Public float
$25.65M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-8 reverse, Jun 1, 2026; 1-for-10 reverse, Jul 17, 2020
SEC CIK
1178253
CUSIP
811292309
ISIN
US8112923094
FIGI
BBG002133YW4
Share class FIGI
BBG002133YY2
LEI
529900XBHFGMNTU70154
EIN
56-2181648

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Gonzalez David AnguloChief Executive Officer, Director1,357,126
Sanjay SubramanianChief Financial Officer–
ivor MacleodChief Financial Officer398,529
Scott SukenickChief Legal Officer574,539
Steven Keith BurkeDirector5,750
Guy MacdonaldDirector12,625
Armando AnidoDirector11,750
Ann HanhamDirector11,577
Brian Philippe TinmouthDirector12,125
David C. HastingsDirector11,522
Steven C. GilmanDirector70,000

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.54M$947.17K$854.93K$41–
FY2024
David Angulo MD
$2.03M$1.43M$1.18M$78–
FY2024
Marco Taglietti MD
$0$0$1.18M$78–
FY2023
David Angulo MD
$1.21M$1.49M$781.80K$143–
FY2023
Marco Taglietti MD
$0$0$781.80K$143–
FY2022$0$0$1.10M$26–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
David Angulo
President and Chief Executive Officer
$626.04K$283.96K$307.31K$312.37K$10.50K$1.54M-24%
Ivor Macleod
Chief Financial Officer
$467.48K$99.91K$108.13K$173.14K$10.50K$859.16K-28%
Scott Sukenick
Chief Legal Officer
$459.96K$99.91K$108.13K$172.21K$10.50K$833.02K-29%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
May 2, 2014
Offer price
$10.00
Securities offered
6,200,000
Gross proceeds
$62.00M
Exchange
Nasdaq
First trading day
May 2, 2014
First-day close
$9.00-10.0%
Lock-up ends (est.)
Oct 29, 2014

“The initial public offering price is $10.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 1, 2026, we had 18 employees, all of whom were employed on a full-time basis.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?